Lv1
78 积分 2023-11-07 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
1天前
已完结
A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
3天前
已完结
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death‐1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105‐204)
4天前
已完结
PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study
7天前
已完结
Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer
7天前
已完结
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
8天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
10天前
已完结
Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design
13天前
已完结
Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma
21天前
已完结
Characterization of the human Ly‐6 antigens, the newly annotated member Ly‐6K included, as molecular markers for head‐and‐neck squamous cell carcinoma
21天前
已完结
皖公网安备34019202002308
